Gilles Gagnon Joins Ceapro Board
EDMONTON, ALBERTA -- (MARKET WIRE) -- 09/11/07 -- Ceapro Inc. (TSX VENTURE: CZO) a Canadian growth-stage biotechnology company is delighted to announce that Gilles Gagnon, with 25 years experience in healthcare and pharmaceutical organizations, most recently as President and CEO of AEterna Zentaris, has joined the Board, effective immediately. His extensive managerial experience, especially in mergers and acquisitions, as well as his inside knowledge of the pharma world will aid Ceapro in executing its growth strategy - to be a global leader in developing and commercializing products for human and animal health markets.
"Ceapro is a promising company with a compelling story of innovation in health-based technologies based on solid science," said Gilles Gagnon. "They are moving from pure research in natural ingredients, through product development to international commercialization."
Added Ceapro Chairman Ed Taylor, "With Gilles's hands-on experience, we will develop our vision into viable business practices, focusing on bringing Ceapro to the next level of success and business maturity - as a global biotechnology company."
This Board position is being filled as John Yewchuk, President and CEO of Thermo King Western Ltd, who has been on Ceapro's board since 1999, is stepping down. His important contribution over the years is well appreciated.
About Gilles Gagnon
Prior to forming his pharmaceutical consultancy firm, Prodev Pharma Inc., Gilles Gagnon held several senior executive positions: President and COO, then CEO at AEterna Zentaris; VP External Affairs at Novartis Pharmaceuticals; Executive Director, Corporate Planning and Administration at Sandoz Canada, Inc., to name a few. Throughout his career, in addition to general management functions, he has been particularly involved in corporate development, alliance management, as well as marketing functions. In this capacity he participated in the launch of nine innovative pharmaceutical products. He has also participated in several international committees and strategic advisory boards, holds post-graduate degrees in pharmacology (M.Sc.) and administration (M.B.A) from the UniversitÃ¯Â¿1/2 de Sherbrooke, as well as a certificate in General Management from the London Business School, UK.
About Ceapro Inc.
Ceapro Technology Inc., Ceapro Veterinary Products Inc., Ceapro Active Ingredients Inc. and Ceapro Bioenergy Inc. are wholly owned subsidiaries of Ceapro Inc., which is a Canadian growth-stage biotechnology company. Our primary business activities relate to the development and commercialization of organic products for medical, cosmetic and animal health industries using proprietary technology and natural, renewable resources. We will be applying our technology to become an active participant in the bioenergy sector. We have also introduced health and wellness services employing our CeaProve® diagnostic technology. Ceapro shares trade on the Canadian TSX Venture Exchange under the symbol CZO. To learn more about Ceapro, visit www.ceapro.com .
This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
The TSX Venture has neither approved nor disapproved of the information contained herein
Contacts: Ceapro Inc. Dr. Mark Redmond President and CEO Telephone (Edmonton): 780-421-4555 Sun International Communications Nicole Blanchard, B.Sc., B.Comm. Managing Partner Telephone (Montreal): 450-627-6600
Released September 11, 2007